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a b s t r a c t
Huntington disease (HD) is a degenerative brain disease clinically manifested by the
characteristic triad: physical symptoms including involuntary movements and poor coor-
dination, cognitive changes with less ability to organize routine tasks, and some emotional
and behavioral disturbances. For patients with HD, feeding is one of the problems they have
to face. People with HD often have lower than average body weight and struggle with
malnutrition. As a part of therapy, good nutrition is an intervention maintaining health and
functional ability for maximally prolonged time. In the early stages of HD, small amounts of
blenderized foods given orally are recommended. In more advanced stages, enteral nutrition
is essential using gastric, or jejunal tubes for short term. Most severe cases require gastro-
stomy or gastrojejunostomy. Although enteral feeding is well tolerated by most of the
patients, a number of complications may occur, including damage to the nose, pharynx, or
esophagus, aspiration pneumonia, sinusitis, metabolic imbalances due to improper nutrient
and ﬂuid supply, adverse effects affecting gastrointestinal system, and refeeding syndrome.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
Available online at www.sciencedirect.com
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journal homepage: http://www.elsevier.com/locate/pjnns1. Introduction
Huntington disease (HD), is a progressive neurodegenerative
disease caused by genetic defect on short arm of chromosome 4
associated with the expansion of a CAG trinucleotide repeat in a
novel gene. The clinical diagnosis is based on the presence of
typical symptoms, positive family history, and genetic tests* Corresponding author at: Department of Physiology, Poznan Univers
Poland.
E-mail address: physioplus@wp.pl (M. Gibas-Dorna).
http://dx.doi.org/10.1016/j.pjnns.2014.10.006
0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Uconﬁrming HD mutation. The duration of the disease from the
time the ﬁrst symptoms appear is extremely variable, but
typically ranges from 15 to 18 years [1]. Neuronal degeneration
causes patients with HD to have problems with movement,
cognition and psychiatric symptoms [2]. As disease progresses
the vital functions including coordination, self-care, eating and
eventually swallowing efﬁciency may decline signiﬁcantly. For
this reason affected individuals may suffer from unbalancedity of Medical Science, Poland Ul. Święcickiego 6, 60-781 Poznań,
rban & Partner Sp. z o.o. All rights reserved.
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care. In patients with HD both energy consumption and
expenditure could be involved in the development of malnutri-
tion. Inadequate caloric intake usually results from: swallow
incoordination, choking on liquids, coughing on foods, masti-
cation difﬁculties, solid food dysphagia, or food-preparation
difﬁculties [3,4]. Patients with increased appetite and high
calorie intake also present with lowered body weight. Because
there is no evidence they have problems with malabsorption,
the increased energy expenditure is suggested mostly due to the
hyperkinetic movement disorder [5,6]. The overall mechanisms
responsible for malnutrition in patients with HD could be
multifactorial and more complex than energy intake-expendi-
ture imbalance caused by major motor disabilities. Reports
indicate degeneration of orexigenic neurons that synthesize
neuropeptides (neuropeptide Y, agouti-related peptide, and
GABA) stimulating hypothalamic hunger center [7], suggest
energy metabolic deﬁcits leading to generalized body mass loss
[8,9], or underline association between higher CAG repeat
number and faster rate of weight loss [10].
There is no successful cure for HD and medications are for
calming symptoms that accompany progression of the
disease. In 2003 The European Huntington's Disease Network
(EHDN) was formed, to provide a platform for clinicians and
families to work together to ﬁnd a cure for HD, and to
coordinate worldwide research. Considering the proper care in
a holistic way, nutritional support is one of the basic
interventions that may prolong patient's life and improve life
quality. For people coping with HD, support can come from
variety organizations, societies and home care services e.g.
Turning Point Scotland, and SHAPE project (Supporting
Huntington's and Promoting Equality), Polish Society of
Huntington Disease, International Huntington Organization
and many others. The home care services provide varying
levels of domestic help, meal programs, and nursing assis-
tance.
2. Symptoms
Patients with HD experience movement, cognitive and
psychiatric disorders. The symptoms usually are discrete or
not present until people are in their thirties and forties.
An early-stage manifestations are not very obvious and
include motor clumsiness, ﬁdgeting, excessive restlessness,
less ability to organize routine tasks. Intellectual and emo-
tional symptoms often occur prior to the motor dysfunction
and may include difﬁculty organizing and focusing on tasks,
problems with attention and judgment, irritability and
depression [11]. Some of the individuals develop schizophre-
nia-like psychosis. If physical symptoms have not yet begun,
these patients might be misdiagnosed as having schizophrenia
[12]. As HD progresses the early physical, intellectual and
emotional symptoms become more evident.
The most characteristic are the uncontrolled body move-
ments that occur spontaneously and develop gradually in
different parts of the body. At early stages facial grimacing and
pouting may occur together with rapid leg and arm movement.
The gait is swaying and ‘‘dancing’’ from side to side, and may
be disrupted by characteristic for HD sudden hyperextensionat hips with a resulting danger of falling backwards. Ocular
motor abnormalities present in a form of inability to suppress
reﬂexive glances to suddenly appearing novel visual stimuli
and delayed initiation of voluntary saccades. Problem with
movement is most evident during the daily activity and
disappears when the individual is asleep [13].
Patients in the mid-stage of HD present with more evident
motor disabilities, swallowing difﬁculties and involuntary
movements create dysphagia. Problems with impulse control
and acting without thinking, difﬁculty memorizing and
signiﬁcant intellectual decline make them less productive
and often individuals have to cease the work at that time.
Memory deﬁcits, and apathy tend to appear as HD progresses,
often in the late phase of the disease [14].
Late-stage occurs when the patient cannot live without
professional help and when self-care is no longer possible.
Individuals experience deep cognitive impairment with apa-
thy and even dementia, severe generalized motor disturbance
and often malnutrition [15].
Low weight and unintentional weight loss are common and
recognized throughout all stages of HD and, as mentioned
before, etiology is multifactorial.
To classify the most common signs of HD into progression
stages Kirkwood et al. prepared a survey of individuals with
symptomatic HD completed by a ﬁrst-degree relative. The
study included 1238 individuals with a minimum of a 6-year
history of symptomatic HD [16]. Classiﬁcation of major
symptoms according to the six onset periods from the
beginning to the late stage of HD according to Kirkwood
et al. presents Table 1.
3. Dysphagia
By the middle stage of HD patients may experience trouble
chewing, drinking and swallowing which are called dysphagia.
The warning signs associated with dysphagia include de-
creased alertness (e.g. playing with food, or taking to large or
repeated bites without swallowing), coughing or choking on
food and drink, gurgly voice especially after eating/drinking,
food or liquid left in the mouth after swallow, recurrent
respiratory infections [17]. Difﬁculty with swallowing usually
occur in all three phases: oral (difﬁculty chewing or forming
bolus), pharyngeal and esophageal. The pathomechanism is
mostly based on deregulation of throat smooth muscle
function, food aspiration around epiglottis and glottis, and
esophageal motor dysfunction. If the esophageal phase is
affected then the esophageal transit time is much longer than
normally, and esophageal peristalsis is impaired and often
reversed (reﬂux). In some cases asymptomatic food aspira-
tions (‘‘silent’’ aspiration) from piriform sinuses may occur
leading to aspiration pneumonia and even death [18].
Many symptoms in patients with HD may interfere with
eating. Worsening of neurological condition may cause an
individual to become distracted and overwhelmed by meal-
time activity. In 2014 Heemskerk et al. developed a valid and
reliable 11-item scale to measure the severity of dysphagia in
HD [19]. This Swallowing Disturbance Questionnaire could be
very helpful when making decision about referral to a speech-
language therapist (SLT) and further assessment including
Table 1 – Classification of major symptoms according to the six onset periods from the beginning to the late stage of HD
according to Kirkwood et al [16].
Earliest
reported
symptom
Early symptom Early-Middle symptom Middle symptom Middle-Late symptom Late symptom
Within 1st year Less than 5 years into disease
progression, equally
represented between the
within-1-year category and
the 2-to-5-year category
2–5 years after HD onset In the 2- to 5-year and
6- to 10-year range in
ap-proximately equal
percentages
Typically 6–10
years after
disease onset
More than 10
years
Symptoms
Involuntary
movements
Sadness Clumsiness Unsteadi-ness Speech difﬁculty Loss of bovel
control
Depression Lack of motivation Trouble holding onto
things
Weight loss Loss of bladder
control
Difﬁcult to get along with Sexual problems Trouble walking
Suspiciousness/
para-noia
Sleeping trouble
Intellectual decline
Memory loss
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consistencies of food/liquids are consumed, or instrumental
assessment like video ﬂuoroscopy. Based on the assessment
results, SLT recommends speciﬁc strategies for safe swallow-
ing or proposes changes in food and liquid consistency to
reduce risk of silent aspiration [20].
4. Malnutrition
The World Health Organization (WHO) deﬁnes malnutrition
as the cellular imbalance between the supply of nutrients
and energy and the body's demand for them to ensure
growth, maintenance, and speciﬁc functions. In HD long
lasting problem with eating, changed cellular energy metab-
olism, increased energy expenditure, and impaired hypo-
thalamic food intake control may ﬁnally change the patient's
nutritional status from lowered body weight to malnutrition.
This, in turn, directly increases morbidity and mortality rate,
length of hospitalization and costs of treatment, and as a
factor contributing to the severity of the disease markedly
decreases efﬁciency of the pharmacological and surgical
management [21]. Consequences of malnutrition could be
classiﬁed as primary and secondary. The primary are:
reduced body mass caused by loss of muscles and adiposeTable 2 – Indications for nutritional support in patients with H
(EHDN) Dietitians Group [18].
Malnourished patients 
Unintentional
weight loss
> 10% within
the last 3–6
months
BMI < 20 kg/m2
and unintentional
weight loss > 5%
within the last
3–6 months
BMI < 20 kg/m2tissue, lowered muscle strength and immunity, hypochromic
anemia, decreased serum protein concentration, distur-
bances with absorption and digestion, and ﬁnally im-
pairment of all organs function. Secondary consequences
of malnutrition include: increased vulnerability to infections,
impaired wound healing, intestinal anastomotic leakage,
increased morbidity and mortality rate, and high costs of
treatment [22].
The assessment of malnutrition degree is based on
nutrition interview, physical examination and biochemical,
immunological and anthropometric parameters. Obtained
results, when considered together, help to identify malnour-
ished patients and prepare an optimal strategy for nutritional
management. The EHDN Dietitians Group suggests nutritional
support in malnourished patients with HD to maintain
optimal healthy weight (BMI 23–25) [23]. Detailed indications
are summarized in Table 2.
5. Oral nutrition
5.1. General considerations
An adequate dietary guidance that provides for individual
patient's needs and strategy for family/guardian support isD according to European Huntington's Disease Network
Patients at risk of malnutrition
Patients who
have eaten
little or
nothing for
more than
5 days and/or
are likely to
eat little or
nothing for 5
days or longer
Patients who
have food
intake below
50–75% in
preceding week
Patients who have
poor absorptive
capacity and/or high
nutrient losses
and/or increased
nutritional needs
from causes such
as catabolism
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nutritional management are: reduction of protein and calories
deﬁciency, maintenance of electrolyte and ﬂuid balance,
control of body weight avoiding rapid weight loss, lowering
of catabolic rate and excessive protein breakdown [24,25].
5.2. Calorie intake, protein and fat supply
According to the evidence-based recommendations summa-
rized by the EHDN Dietitians Group, patients with HD should
receive 25–35 kcal/kg/day total energy (including that derived
from protein). The daily calorie intake should be gradually
elevated until the target calorie intake for patients with HD is
reached. Ratio of fat and carbohydrate should stay at the same
level as normal population. The recommended protein supply
should be at the level of 0.8–1.5 g protein (0.13–0.24 g nitrogen)/
kg/day and at least 50% of ingested proteins should be of an
animal origin. The baseline ﬂuid intake should oscillate at the
level of 30–35 ml ﬂuid/kg (with allowance for any extra
requirements, input of ﬂuid from other sources and any
additional losses), however, in some individuals ﬂuid require-
ments may be higher. The diet may be supplemented with oral
protein supplements, which appear to have high clinical
beneﬁts resulting in improvements in patients' anabolic rate.
Normally, 25% of daily energy requirement is covered by
dietary lipids (daily intake of fats equals 1.5 g per kg of body
weight). Some types of fats have speciﬁc health beneﬁts, while
others are detrimental. Trans fats from processed foods,
saturated fats and heating to the very high temperature fats
can evoke production of harmful free radicals. The types of
potentially helpful dietary fat are mostly unsaturated and they
include monounsaturated and polyunsaturated fats, and
omega-3 fatty acids. The examples are oils (olive oil, sunﬂower
oil, peanut oil and corn oil, avocado oil, walnut oil, evening
primrose oil, borage seed oil, and ﬂax seed oil) and ﬁshes
(salmon, tuna, trout, mackerel, sardines and herring) [23].
5.3. Nutrition in different stages of HD
Nutritional assessment and care planning for individuals with
HD must take into account the stage of the disease and the
feeding difﬁculties individuals may experience.
In the early stages of HD lowered mood of an individual
may contribute to the changes in eating habits with cravings
for carbohydrates. If the diet is well balanced then frequent
and smaller meals are recommended without any other
noticeable changes. Fruits and vegetables are a rich source
of antioxidants, micronutrients and vitamins, moreover they
help to improve visual appeal that enhances ﬂavor experi-
ences. Thus, the diet should incorporate colored and healthy
plant foods.
In the midstage, because of dysphagia the meals should be
based on moist and soft foods. Before being blended food
should be steamed as it helps to reduce a nutrient loss.
The samples of recommended meals include: full fat milk
shakes, fruit/vegetable mousse, mashed potatoes with butter,
creamed soups and sauces, scrambled eggs, puddings,
gelatins, creamed cereals, lean meat cut into small pieces,
mayonnaise and full-fat salad dressings [26]. Patients should
avoid eating when tired and upset, they should eat slowly andstay in the upright position during and 30 min after meal,
when eating they should take small bites (1/2 teaspoon or less)
and chew well.
Patients who have or are at risk of malnutrition can be
managed with dietary modiﬁcation, nutritional supplements
and dietetic counseling. The amount of delivered proteins
should be elevated above normal dietary limits and include all
exogenous amino acids that stimulate human muscle anabo-
lism. Fattening diet serves for an accumulation of the energy
sources, which are depleted due to the intense catabolism in
HD patients. Although dietary fats are the most concentrated
source of calories in the diet, malnourished patients should
avoid overloading their diet with fatty substances because a
feeling of discomfort may occur. The person with HD may need
to get more nutrition from a smaller volume of food, so the
number of meals per day should be 6–8 and high-calorie
snacks plus extra calories in regular recipes are necessary to
maintain body weight. Additionally, to increase an appetite,
everyday menu should be varied and meals should be nicely
prepared [27].
In the advanced stages, when it is no longer possible to
meet the patient's nutritional needs with an oral diet, enteral
feeding is considered. The decision on non-oral methods of
feeding should be made in conjunction with the patient,
family, dieticians and medical team. To agree the details of
nutritional management patients must obtain sufﬁcient
information about their treatment in the context of quality
of life. When the patient is still in a quite good mental
condition it is worth discussing the future possibilities of
therapy, explaining the proﬁts and risks, and ensuring that
patient makes informed decisions and gives consent based on
good information. However, because of a decline in a cognitive
ability and decision making skills, discussing enteral feeding
with patients is very difﬁcult. When the patient is legally
incapacitated the decision, according to the Polish law,
belongs to legal guardian and the court.
5.4. Enteral nutrition
Enteral nutrition (EN) is an administration of special food
mixture containing protein, carbohydrates, fats, vitamins, and
minerals through the tube directly to the stomach or
intestines. Tube feedings may be used to supplement oral
intake of food and ﬂuids, or they may become the primary
source of nutrition.
EN represents one of the nutritional management meth-
ods that, according to the ESPEN (European Sociecty of
Parenteral Nutrition and Metabolism), consists of speciﬁc
liquid nutitional preparations given orally as a dietary
supplements, through nasogastric or nasoenteral feeding
tube, and by gastrostomy or jejunostomy [28]. EN uses and
maintains absorption and digestion in the gastrointestinal
(GI) tract and is preferred to parenteral feeding as it is more
physiological and has fewer side effects. When compared
with parenteral nutrition, EN avoids bacterial translocation,
prevents abnormalities of liver and biliary function, helps to
prevent mucosal atrophy, gastroenteritis or ulcer disease.
However, the upper part of GI system is not involved in the
digestion process [29,30]. Although EN has a number of
undisputed advantages, it can be considered only if the
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‘‘If the gut works use it’’. Complete intestinal obstruction,
failure of intestinal function, severe gastrointestinal inﬂam-
mation, chronic diarrhea, or malabsorption represent major
contraindications to EN. Selection of the enteral access device
depends, among others, on expected duration of EN. Feedings
are either ‘‘continuous’’ or ‘‘bolus’’ servings. Most patients
who are just starting out on tube feedings are given
continuous feedings, then gradually changed over to bolus
feedings. For short term use (less than four weeks) the
nasogastric/enteric tube is the most commonly used method.
The tube can be placed in the stomach, duodenum or
jejunum. In patients requiring long term (more than 4 weeks)
EN tube enterostomies are used (gastro- or jejunostomy) [31].
The nasogastric tubes are used if there are indications to
short-term EN. Before connecting the tube to administration
set and start feeding, the position of the tube must be checked
by X-ray control, ﬁber optics, aspiration of stomach juice, and
stethoscope during air injection. Disorders with high risk of
gastric juice reﬂux and regurgitation should be excluded from
feeding by gastric tube. In these cases duodenal or jejunal
tubes are more safe and recommended. Large bore tubes
made from PCV may be helpful in home made diet
administration. However, a number of complications may
occur, including: bacterial contamination, nasal septum
necrosis, esophageal necrosis and perforation, otitis media
and sinusitis, gastroesophageal reﬂux, aspiration pneumo-
nia. Therefore, tubes for gastric drainage and home made
diets should not be used for more than 10 days. For longer EN
(up to 6 weeks) small bore naso-enteric feeding tubes areTable 3 – Enteral nutrition – general types of feed.
Type of feed 
Polymeric feeds Whole protein as a ni
maltodextrins or starc
oil as a fat source 
elements.
Oligomeric feeds Dipeptides, tripeptide
nitrogen source. Fat in
triglycerides. Carbohy
elements. Lower osmo
Predigested
elemental feeds
Protein in the form of
mixture of free amin
Carbohydrate as a pa
chain lengths of gluco
amounts of fat in the
and/or essential fatty 
Disease speciﬁc
feeds
Liver formulas Branched chain amin
amino AIDS deﬁcient 
Renal formulas The formulas vary in 
mineral content. Ge
calorically dense an
magnesium and phos
formulas.
Pulmonary formulas Modiﬁed carbohydrate
CO2 production from 
Immunomodulary
formulas
Glutamine, arginine, o
branched chain amino
Gastrointestinal
dysfunction formulas
Oligomeric feed plus s
ﬁber.
Diabetes formulas Standard feed or 15% 
and 55% from carbohyusually preferred. Using tubes that are small in diameter
requires liquid commercial enteral formulas administration
[32,33]. Percutaneous endoscopic gastrostomy (PEG) is one of
more permanent access routes for long-term EN, that can be
performed nonsurgically with gastroscopic guidance. For
patients requiring long-lasting (months-years) enteral feed-
ing, PEG is better alternative that avoids occurrence of adverse
effects related with nasoenteral tubes (regurgitation, nausea,
diarrhea). PEG feeding catheters, made from silicone, are
hypoalergic, well tolerated and do not cause development of
sores. If necessary they may be easily removed and replaced.
The indications for PEG reﬂect difﬁculties with oral intake
often where obstruction to the upper airway or gastrointesti-
nal tract or makes passing a nasogastric tube difﬁcult e.g.
unsafe swallowing, problems with chewing [34].
The choice of adequate feed administered to the patient
with HD decides about safety and efﬁciency of dietary
treatment. A wide variety of feeds is available [35], the most
common types of formulas are shown in Table 3.
The dietitian, in consultation with doctors and other
health professionals, decides which type of feed and route of
feeding is most suitable for the patient. Formulas are in a
liquid form and contain high biological value proteins
(usually from milk, casein and soya), healthy fats (from
vegetable oils), carbohydrates (glucose polymers, maltodex-
trin, starch). The content of electrolytes, minerals, micro-
nutrients and vitamins is carefully calculated to avoid excess
intake, and should reﬂect individual's daily needs. When
delivering enteral feeding patient's medications should be in
a liquid form or dispersible/soluble formulations and must beComposition Indications
trogen source, oligosaccharides,
h as a carbohydrate source, vegetable
and minerals, vitamins and trace
Patients with near-
normal gut function
s and some free amino acids as a
 the form of long and medium chain
drates, minerals, vitamins and trace
lality than elemental diets.
 partial hydrolysates and comprise a
o acids, dipeptides, and tripeptides.
rtially digested starch with various
se polymers (maltodextrins). Variable
 form of medium chain triglycerides
acids. Diet highly osmotic.
Patients with a degree
of malabsorption
o acids enriched and aromatic chain
formulas.
Chronic encephalopathy,
advanced cirrhosis
protein, electrolyte, vitamin and
nerally they are lower in protein,
d have lower levels of potassium,
phorus when compared to standard
Kidney failure (except
patients on dialysis, who
require higher protein
content in a diet)
 and fat nutrition formulas (to reduce
carbohydrates).
COPD, ARDS
mega-3 fatty acids, nucleotides and
 acids.
upplementation of glutamine and
of calories from protein, 30% from fat
drates.
Hyperglycemic critically
ill patients
Table 4 – Most common complications of enteral nutrition.
Gastrointestinal Biochemical Mechanical Others
Diarrhea or constipation Deﬁciency of vitamins
(e.g. Thiaminea), minerals,
trace elements
Pulmonary aspiration Sinusitis, otitis media
Bloating Hypo-/hypernatremia Tube malposition Oesophageal erosions,
oesophagitis
Regurgitation Dehydration Tube clogging Feed contamination
and resulting infection
Nausea and vomiting Hyperglycaemiaa Gastrointestinal perforation
Reﬂux Hypo-a/hyperkalaemia
Interactions with drugs Hypophosphataemiaa
Malabsorption/maldigestion Hypomagnesaemiaa
Hypozincaemia
a Symptoms that may indicate refeeding syndrome.
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administration problems.
There are three methods of formula administration: (1)
bolus feeding (without usage of the pump), and (2) continuous
feeding (feeding over 16–20 h). Continuous feeding requires a
break of at least 4 h in 24 h to allow the stomach to re-acidify.
In continuous feeding the formula can be delivered overnight
or during the day depending on patient's condition. Bolus
feeding involves the delivery of 200–400 ml over a period of 15–
60 min and can be given 4–6 times a day. In a gastric feeding
the most optimal are small servings 200–300 ml administered
within 30–40 min ensuring good emptying of a stomach.
Before the next serving is administrated aspiration of the
gastric content by enteral syringe is necessary to ensure if
there is no retention of stomach content [36].
Detailed guidelines regarding equipment and procedure of
administration of feed plus recommendations for staff
training and practice are widely described in the literature [37].
The clinical and laboratory monitoring of nutritional
treatment includes review of the indications, route, risks,
beneﬁts and goals of nutrition support at regular intervals.
Feed and water ﬂushes should be recorded on a daily ﬂuid
balance chart. The comprehensive protocols provided by
National Institute for Health and Care Excellence in London
(NICE) help to control nutritional, anthropometric and clinical
condition monitoring of nutrition support and separately
detailed laboratory monitoring. The time interval between
reviews depends on the patient, care setting and duration of
nutrition support [23].
In most cases enteral feeding is well tolerated, however an
adverse effects may occur. The most common complications
are summarized in Table 4.
Some of them are associated with refeeding syndrome
(RS), which can be deﬁned as the potentially fatal shifts in
ﬂuids and electrolytes that may occur in malnourished
patients receiving artiﬁcial refeeding [38]. RS may develop
in malnourished patients who start enteral feeding as a result
of a sudden shift from fat to carbohydrate metabolism and
increased insulin secretion. Insulin stimulates glycogen, fat,
and protein synthesis. This process requires minerals such as
phosphate and magnesium and cofactors such as thiamine.
Cells absorb and use more potassium, magnesium, phos-
phate, and water follows by osmosis. Finally deﬁciency ofserum phosphate, potassium, magnesium, and thiamine may
lead to the clinical features of RS, including rhabdomyolysis,
leukocyte dysfunction, respiratory failure, cardiac failure,
hypotension, arrhythmias, seizures, coma, and sudden death
[39,40].
6. Conclusions
In summary, there is no cure currently available for patients
with HD, thus good nutrition appears to be one of the
interventions maintaining health and functional ability for
maximally prolonged time. The type of food and way of
feeding differ according to the stage of disease and feeding
difﬁculties individuals may experience. When oral feeding is
no more possible enteral feeding is recommended. Based on
the current clinical guidelines, standard formula should be
the product of choice for the majority of patients requiring
enteral feeding [41]. Optimal nutritional assessment and
care planning must include appropriate feeding techniques,
regular monitoring of nutritional intake, weight changes plus
overall patient's condition and effective communication
between patient, family members and healthcare profes-
sionals.
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